arrow_back Back Filing freshness 10-Q Q2 FY2024 SEC EDGAR

AXIM BIOTECHNOLOGIES, INC.

AXIM
Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
44 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
58
Health
Fair
Bullish
auto_awesome

Analytical Summary

AXIM BIOTECHNOLOGIES, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth 76.0%
Op. Margin None
ROIC 16.0%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.63
info Valuation on last close.

44-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.48K
↑ +76.0%
Net Income Profit after all expenses
$-292.30K
↑ +92.1%
FCF / Share Free cash flow per share
$-0.00
↑ +39.6%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Financial Health
23
Cash Quality
24

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 44 quarters